News | August 29, 2011

Echo Response to CRT Impacts Long-Term Survival

August 29, 2011— The echocardiographic response (reduction of left ventricular end-systolic volume), evaluated at six months follow-up, proved a better predictor of long-term mortality than clinical status improvement in a large population of cardiac resychronization therapy (CRT) patients. Therefore, assessment of occurrence of left ventricular reverse remodeling at mid-term follow-up may be an adequate surrogate endpoint in heart failure patients treated with CRT.

CRT efficacy has been demonstrated with significant reductions in mortality and morbidity of heart failure patients. Many studies have evaluated its efficacy via heart failure symptom improvement (clinical response) or left ventricular volume reduction (left ventricular reverse remodeling) at mid-term follow-up (3 or 6 months after CRT implantation). Echocardiographic response is also used for evaluation.

Based on these surrogate end points, the efficacy of CRT may change significantly and, consequentially, definition of response to CRT is still debated. Ideally, these surrogate end points should determine a significant reduction in mortality. Accordingly, the present evaluation investigated which definition of CRT response at mid-term follow-up best predicts long-term mortality.

A total of 663 advanced heart failure patients were followed-up for the occurrence of all-cause mortality. At six months, the clinical and echocardiographic responses to CRT were evaluated. Clinical response was defined as a reduction in New York Heart Association (NYHA) functional class of at least one point; echocardiographic response was defined by a reduction in left ventricular end-systolic volume of at least 15 percent. Based on these definitions, 510 (77 percent) patients showed clinical response and 412 (62 percent) patients showed echocardiographic response to CRT.

During a mean follow-up of 37±22 months, 140 (21 percent) patients died. Clinical and echocardiographic CRT responses were both significantly related to all-cause mortality. However, only echocardiographic response to CRT was independently associated with a superior survival. In particular, a patient not showing echocardiographic response had a risk of death three times higher than a patient showing a good echocardiographic response (hazard ratio 0.38; 95 percent confidence intervals, 0.27-0.50; p<0.001).

The figure shows the probability of all-cause mortality, which differed significantly between the two groups dichotomized based on the echocardiographic response (left ventricular reverse remodeling). A cumulative 1 percent, 4 percent and 8 percent of patients with LV reverse remodeling died by 12, 24 and 36 months follow-up, respectively. In contrast, a respective 8 percent, 19 percent and 27 percent of the patients without LV reverse remodeling died during the same time period (log-rank p <0.001).

The present findings have important implications in the design process of clinical trials. Use of biological markers in the prevention and progression of heart failure (such as changes in left ventricular volumes and function) allow investigators to make prompt evaluations of heart failure therapies; it also helps to understand the biologic processes underlying the disease and the mechanisms of the therapy. In addition, the use of these surrogate end points permits smaller sample size, shorter trial duration and reduced costs.

In conclusion, the echocardiographic response, evaluated at 6 months follow-up, demonstrated to be a better predictor of long-term mortality than improvement in clinical status in a large population of CRT patients. Therefore, assessment of occurrence of left ventricular reverse remodeling at mid-term follow-up may be an adequate surrogate end point in heart failure patients treated with CRT.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init